Globus Medical Q2 FY2026 Earnings Call
With Keith Pfeil (President and CEO) and Kyle Kline (CFO).
Globus Medical, Inc. is a leading musculoskeletal solutions company and is driving significant technological advancements across a complete suite of products. Founded in 2003, Globus’ single-minded focus on advancing surgery has made it the fastest growing company in the history of orthopedics.
More about Globus Medical
Globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients. Additional information can be accessed at www.globusmedical.com. IMPORTANT NOTICE TO JOB APPLICANTS: POTENTIAL FRAUD ALERT. Globus Medical has been made aware of an online scam where unknown entities are posing as Globus Medical recruiters in an attempt to obtain personal information as part of our application or job offer process. Before providing any personal information to outside parties, please verify the following: • All legitimate Globus Medical recruiter email addresses end with “@globusmedical.com” • No application process should include a cloud-based document (ex. Google doc) asking for personal information • The position described is found on our careers site at globusmedical.com/careers.
1Prepared remarks3 speakers
Thank you, Sarah, and thank you everyone for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, Kyle Kline, Chief Financial Officer. This review is being made available via webcast, accessible through the investor relations section of the globusmedical.com website. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.
Our Form 10-K for the 2025 fiscal year and…
Thanks, Brian, good afternoon, everyone. Thank you for joining us on today's call. We completed an exceptional Q2, positioning us for a strong 2026 as we move into the second half of the year. At a top level, Q2 revenue was $789.6 million, growing 6% as reported. Excluding Nevro, Q2 revenue growth was 9%, led by 7% U.S. spine growth and 14% growth in international spine. Fully diluted non-GAAP earnings per share was $1.34, growing 56% compared to the prior year quarter, while Q2 adjusted EBITDA was 35.4%, growing…
Thanks, Keith, and good afternoon, everyone. Our Q2 results delivered above-market top-line growth, including share-taking domestic and international spine sales growth, our seventh consecutive quarter of adjusted gross profit margin expansion, and a quarterly record for fully diluted non-GAAP earnings per share. Sales grew 6% as reported, compared to the Q2 of the prior year, with 9% growth in the base business excluding Nevro. U.S. Spine, again, led the way in growth for the organization, up over 7% compared to…